{"id":"https://openalex.org/W159077070","doi":null,"title":"Ipilimumab for pre-treated patients with advanced/metastatic melanoma","display_name":"Ipilimumab for pre-treated patients with advanced/metastatic melanoma","publication_year":2011,"publication_date":"2011-01-01","ids":{"openalex":"https://openalex.org/W159077070","mag":"159077070"},"language":"en","primary_location":{"id":"mag:159077070","doi":null,"is_oa":false,"landing_page_url":"http://eprints.aihta.at/905/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5032291905","display_name":"Anna Nachtnebel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"A. Nachtnebel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5032291905"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.01679084,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.009600000455975533,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":1.0},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9179999828338623},{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.8849999904632568},{"id":"https://openalex.org/keywords/previously-treated-patients","display_name":"previously treated patients","score":0.8460000157356262},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6959999799728394},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.6610000133514404},{"id":"https://openalex.org/keywords/ctla-4-blockade","display_name":"CTLA-4 blockade","score":0.6480000019073486},{"id":"https://openalex.org/keywords/cancer-vaccines","display_name":"cancer vaccines","score":0.46000000834465027},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7940000295639038},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.7170000076293945}],"concepts":[{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.9899312257766724},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8769242167472839},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.831106424331665},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.7121490836143494},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5987741947174072},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5922389626502991},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5785200595855713},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.5204694271087646},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.39635610580444336},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.30510783195495605},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.23995530605316162},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2164452075958252},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.12874767184257507}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:159077070","doi":null,"is_oa":false,"landing_page_url":"http://eprints.aihta.at/905/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1994786993","https://openalex.org/W4300561334","https://openalex.org/W2095826876","https://openalex.org/W2254875398","https://openalex.org/W2344981827","https://openalex.org/W2530644109","https://openalex.org/W2140521678","https://openalex.org/W2111877246","https://openalex.org/W1601978796","https://openalex.org/W3133533660"],"abstract_inverted_index":{"Ipilimumab,":[0],"a":[1,58,93],"monoclonal":[2],"antibody,":[3],"is":[4,63],"intended":[5],"for":[6,32],"the":[7,64,84],"therapy":[8,44,66],"of":[9,45,86],"pre-treated":[10,73],"patients":[11,33],"with":[12,35],"advanced/metastatic":[13,46],"melanoma.":[14,75],"A":[15],"phase":[16],"III":[17],"study":[18],"showed":[19],"an":[20,40,89],"increase":[21,52],"in":[22,37,53,70,72],"median":[23],"overall":[24],"survival":[25],"(OS)":[26],"by":[27],"more":[28],"than":[29],"3":[30],"months":[31],"treated":[34],"ipilimumab":[36,62,87],"comparison":[38,85],"to":[39,88],"experimental":[41,90],"vaccine.":[42],"As":[43],"melanomas":[47],"proves":[48],"very":[49,101],"difficult,":[50],"this":[51],"OS":[54,71],"can":[55],"be":[56],"called":[57],"success,":[59],"especially":[60],"since":[61],"first":[65],"which":[67],"demonstrated":[68],"improvements":[69],"advanced":[74],"However,":[76],"many":[77],"open":[78],"questions":[79],"still":[80],"remain":[81],"including":[82],"whether":[83],"vaccine":[91],"was":[92],"reasonable":[94],"approach.":[95],"In":[96],"addition,":[97],"adverse":[98],"events":[99],"were":[100],"frequent":[102],"and":[103],"sometimes":[104],"life-threatening.":[105]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-06-24T00:00:00"}